Credit Suisse Ag Tiziana Life Sciences LTD Transaction History

Credit Suisse Ag

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$0.55 - $0.83 $1,375 - $2,075	-2,500 Reduced 45.79%	2,960 $2,000
Q2 2022 Aug 12, 2022	SELL	$0.66 - $1.06 $3,384 - $5,435	-5,128 Reduced 48.43%	5,460 $4,000
Q1 2022 May 16, 2022	BUY	$0.62 - $1.25 $6,564 - $13,235	10,588 New	10,588 $11,000

816K

Ticker TLSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,273,000
Market Cap $88M
Description
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, m...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.